Vir Biotechnology Inc (VIR)
Operating profit margin
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating income (ttm) | US$ in thousands | -684,305 | -695,791 | -314,095 | -324,131 | 833,070 | 1,555,324 | 1,306,975 | 1,593,214 | 420,751 | -259,405 | -293,635 | -383,703 | -296,980 | -252,335 | -212,400 |
| Revenue (ttm) | US$ in thousands | 86,180 | 118,803 | 490,721 | 444,237 | 1,613,740 | 2,377,077 | 2,106,136 | 2,325,891 | 1,095,407 | 284,394 | 182,706 | 72,626 | 76,368 | 75,614 | 75,089 |
| Operating profit margin | -794.04% | -585.67% | -64.01% | -72.96% | 51.62% | 65.43% | 62.06% | 68.50% | 38.41% | -91.21% | -160.71% | -528.33% | -388.88% | -333.71% | -282.86% |
December 31, 2023 calculation
Operating profit margin = Operating income (ttm) ÷ Revenue (ttm)
= $-684,305K ÷ $86,180K
= -794.04%
Vir Biotechnology Inc's operating profit margin saw significant fluctuations over the eight quarters analyzed. The company experienced negative operating profit margins in the most recent two quarters, with Q4 2023 at -794.04% and Q3 2023 at -507.99%, indicating that the company's operating expenses exceeded its gross profit. The negative margins suggest challenges in controlling costs and generating sufficient revenue during those periods.
Prior to the recent downturn, Vir Biotechnology showed more favorable operating profit margins, with Q2 2022 at 61.99% and Q1 2022 at 68.50%. These positive margins indicate the company was able to effectively manage its expenses and generate healthy profits from its operations. However, the margins declined in the subsequent quarters, showcasing a downward trend in profitability.
The data suggests that Vir Biotechnology has faced difficulties in maintaining consistent profitability in recent quarters, pointing to potential issues in cost management and revenue generation. Further analysis of the company's operational efficiency and financial performance drivers may be necessary to address these challenges and improve its overall financial health.
Peer comparison
Dec 31, 2023